Agios Pharmaceuticals Stock News

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha

Agios Pharmaceuticals is a biotech company focused on developing medicines for cancer and rare genetic diseases. The company's financials show growth, with increased product revenue and a reduction in

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2023 Results Conference Call August 3, 2023 8:00 AM ET Company Participants Christopher Taylor - Vice President of Investor Relations Brian Goff - Chief E

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab

CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the

Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.

Schrödinger focuses on drug discovery using an AI platform. The company has already helped bring two therapies to market.

The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab

The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Agios Pharmaceuticals (AGIO). While the effectiveness of this highly sought-after metric is questionab

Agios Pharmaceuticals, Inc. has done well after its pivot to rare diseases. The move has also generated a huge amount of cash.

– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND ® (mitapivat) on Hemoglobin, Hemolysi

The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.